Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis
ObjectiveTo perform a meta-analysis of the efficacy and safety about 177Lu-DOTATATE therapy for advanced/metastatic pNETs based on the current clinical evidence.MethodsThis systematic review follows the PRISMA guideline. Search PubMed, Medline, EMBASE and CNKI, VIP, Wanfang databases, from establish...
Main Authors: | Jiao Ma, Xin Hu, Lanying Li, Zijuan Rao, Chunyin Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.993182/full |
Similar Items
-
Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety
by: MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
Published: (2022-04-01) -
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients
by: Morticia N. Becx, et al.
Published: (2022-11-01) -
Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01) -
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01) -
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
by: Peter Frøhlich Staanum, et al.
Published: (2021-11-01)